eujobs.coEU jobs in brussels
Post a JobHeadhunter

Stichting Health Action International

Acronym: HAI

General Information

Identification Code: 44361352681-84
Website: [object Object]
Entity Form: Stichting
Registration Category: Non-governmental organisations, platforms and networks and similar
Registration Date: 11/30/2009
Last Update: 3/13/2024
EP Accredited Number: 0

Mission & Interests

Goals: Health Action International is a non-profit, independent global network of consumer groups, public interest NGOs, healthcare professionals, academics, and individuals working and interested on pharmaceutical policy issues. HAI’s mission is to increase equitable access to essential medicines and improve their rational use through research excellence and evidence-based advocacy. In Europe, HAI has grown to become a pre-eminent voice in medicines policy intervention/discussion, supported by a strong European network of 125 individual and organization members from 19 European Union (EU) Member States and 14 other non-EU countries. The HAI Europe projects team, based in Amsterdam, is responsible for coordinating the work programmed and related activities within the European region. HAI monitors and advocates on EU policies that affect medicines on three key thematic priorities: Access to Needed Medicines, the Rational Use of Medicines, and the Democratization of Medicines Policy.
Interests Represented: Does not represent commercial interests
Interests:
  • Budget
  • Competition
  • Consumers
  • International co-operation and development
  • Public health
  • Research and innovation
  • Trade
Levels of Interest:
  • national
  • global
  • european

Activities

Main EU Legislative Proposals: HAI advocates for policy initiatives that help to address current shortfalls/shortcomings in access to medicines. In Europe, HAI monitors EU policy initiatives and developments that have an impact on access to medicines, their rational use and on the democratization of medicines policy. We also work on exposing major risks that the use of Artificial Intelligence (AI) in health can cause, including discrimination, harming citizens health and safety, and the exacerbation of health inequalities, which infringes on patients’ fundamental rights. Where needed, we issue recommendations for improvement on specific topics. EU legislation, policies and initiatives of particular interest include: implementation of proposals on EU cooperation on Health Technology Assessment and clinical trials regulation; discussion of European Pharmaceutical Strategy and review of EU pharmaceutical legislation, orphan designation and other IP incentives; European Union IP Action Plan and enforcement strategy, including revision of Supplementary Protection Certificate Regulation; Competition policy; EU trade agreements with impact on access to medicines; Innovative Medicines Initiative and Horizon Europe; Multiannual Financial Framework (MFF); implementation of the One Health Action Plan against AMR; European Medicine Agency (EMA)'s policies and activities; tackling medicines shortages.
Communication Activities: For our publications please visit: https://haiweb.org/publication/ For our press releases and other news please visit: https://haiweb.org/news/ In 2023, we published 12 reports, briefings and consultation responses and hosted a number of events and meetings to discuss and disseminate these. These publications formed the basis of our advocacy work. In the same period, our European project work and staff and members were quoted or mentioned in the media at least 42 times, demonstrating the added value of our published materials and that our staff are seen by media contacts as experts in their field. The European Projects Team has worked closely with the HAI Communications Team to develop engaging content that promoted our work and helped achieve project objectives. We continued the development of the TRIPS Flexibilities Navigator to improve its useability and reach. This living resource designed to help to educate lawmakers, policymakers, researchers, and the public about how the use of TRIPS Flexibilities as a legitimate tool to improve access to patented medicines has received excellent feedback from users.
Inter-institutional or Unofficial Groupings: Artificial intelligence and digital

Head Office

Address: Overtoom, 60/II
Post Code: 1054HK
City: Amsterdam
Country: NETHERLANDS
Phone: [object Object]

EU Office

Address: Overtoom, 60/II
Post Code: 1054HK
City: Amsterdam
Country: NETHERLANDS
Phone: [object Object]

Financial Data

New Organisation: false
Closed Year: [object Object]
Current Year: [object Object]
Complementary Information: N/A

Membership Information

Members10 Percent: 0
Members25 Percent: 2
Members50 Percent: 1
Members75 Percent: 1
Members: 5
Members F T E: 2.75
Info Members: HAI has one full-time policy advisor that is solely focused on our EU projects. He is supported by Admin, Communications, PME & our Executive Director.

Structure

Structure Type: Structure
Is Member Of: Member organisations: BUKO Pharma-Kampagne Public Eye La Revue Prescrire Medico International Medicus Mundi Switzerland Mezis Physicians for Social Responsibility Oxfam GB Salud por Derecho Wemos T1 International Health Projects for Latvia EKPIZO UAEM Partnership for Global Health / plan:g The Independent Diabetes Trust (IDDT) VdPP (Association of Democratic Pharmacists)
Organisation Members: HAI is a member of the European Public Health Alliance (EPHA), the International Society of Drug Bulletins (ISDB), the Transatlantic Consumer Dialogue (TACD), the Medicines in Europe Forum (MiEF), the European Alliance for Responsible R&D and Affordable Medicines, the Antimicrobial Resistance Coalition (ARC), and Global Snakebite Initiative. At the national level HAI is member of the Dutch Global Health Alliance (DGHA) and the Medicijnen Netwerk. In addition, HAI enters into strategic partnership with other associations when collaborating on certain topics thus tapping into extended expertise as required. HAI is in official relations with the WHO and collaborates with the organization on several projects as well as attending governing bodies and ad-hoc meetings. Others: EU Pharmaceutical Strategy IP Package Framework Program 10 HERA work plan EU guidelines and National Action Plans of Member States on Anti-Microbial Resistance European Health- Data Space and the EMA / HMA Big Data Workplan The EU Artificial Intelligence Act The EU AI Liability Directives The EU Medical Devices Regulation European Health Data Space GDPR